Everett Vokes to Mesothelioma
This is a "connection" page, showing publications Everett Vokes has written about Mesothelioma.
Connection Strength
0.946
-
The cancer and leukemia group B respiratory committee. Clin Cancer Res. 2006 Jun 01; 12(11 Pt 2):3581s-8s.
Score: 0.195
-
Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials. Oncologist. 2017 02; 22(2):189-198.
Score: 0.102
-
Novel EPHB4 Receptor Tyrosine Kinase Mutations and Kinomic Pathway Analysis in Lung Cancer. Sci Rep. 2015 Jun 15; 5:10641.
Score: 0.091
-
Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium. Lung Cancer. 2012 Oct; 78(1):76-80.
Score: 0.075
-
Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol. 2012 Jul 10; 30(20):2509-15.
Score: 0.074
-
Phase II study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): a brief report. J Thorac Oncol. 2012 Apr; 7(4):755-9.
Score: 0.073
-
Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107). Lung Cancer. 2012 Jun; 76(3):393-6.
Score: 0.072
-
A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307. J Thorac Oncol. 2010 Oct; 5(10):1655-61.
Score: 0.066
-
Cooperative group research efforts in thoracic malignancies 2009: a review from the 10th Annual International Lung Cancer Congress. Clin Lung Cancer. 2009 Nov; 10(6):395-404.
Score: 0.062
-
Protein kinase C beta in malignant pleural mesothelioma. Anticancer Drugs. 2008 Oct; 19(9):841-8.
Score: 0.057
-
Response to the methylation inhibitor dihydro-5-azacytidine in mesothelioma is not associated with methylation of p16INK4a: results of cancer and leukemia group B 159904. J Thorac Oncol. 2008 Apr; 3(4):417-21.
Score: 0.055
-
MET as a target for treatment of chest tumors. Lung Cancer. 2009 Feb; 63(2):169-79.
Score: 0.014
-
Semiquantitative analysis of dynamic contrast enhanced MRI in cancer patients: Variability and changes in tumor tissue over time. J Magn Reson Imaging. 2004 Jul; 20(1):122-8.
Score: 0.011